Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. N-(4-chloro-3-methyl-5-isoxazolyl)-2-((4,5-(methylenedioxy)-o-toly)acetyl)-3-thiophenesulfonamide
2. N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3,4-(methylenedioxy)-6-methyl)phenylacetyl-3-thiophenesulfonamide
3. Sitaxsentan
4. Tbc 11251
5. Tbc-11251
6. Tbc11251
1. Sitaxsentan
2. 184036-34-8
3. Tbc-11251
4. N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
5. Tbc11251
6. Ipi-1040
7. J9qh779mem
8. Chembl282724
9. N-(4-chloro-3-methyl-5-isoxazolyl)-2-((4,5-(methylenedioxy)-o-toly)acetyl)-3-thiophenesulfonamide
10. N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3,4-(methylenedioxy)-6-methyl)phenylacetyl-3-thiophenesulfonamide
11. Tbc 11251
12. Sitaxentan [inn]
13. Ipi 1040
14. Sitaxentan [usan:inn]
15. Unii-j9qh779mem
16. Sitaxsentan [mi]
17. Sitaxentan (usan/inn)
18. Sitaxentan [usan]
19. Dsstox_cid_31462
20. Dsstox_rid_97348
21. Sitaxentan [who-dd]
22. Dsstox_gsid_57673
23. 3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-((6-methyl-1,3-benzodioxol-5-yl)acetyl)-
24. N-(4-chloro-3-methyl-5-isoxazolyl)-2-((2-methyl-4,5-methylenedioxyphenyl)acetyl)thiophene-3-sulfonamide
25. N-(4-chloro-3-methyl-5-isoxazolyl)-2-((3,4-(methylenedioxy)-6-methylphenyl)acetyl)-3-thiophenesulfonamide
26. Schembl803344
27. Gtpl3950
28. Dtxsid0057673
29. Chebi:135736
30. Bcp13848
31. Zinc1481831
32. Tox21_113725
33. Bdbm50058126
34. Zinc328577260
35. Cs-0402
36. Db06268
37. Sb19551
38. Ncgc00253587-01
39. Hy-76520
40. N-(4-chloro-3-methylisoxazol-5-yl)-2-(2-(6-methylbenzo-[d][1,3]dioxol-5-yl)acetyl)thiophene-3-sulfonamide
41. Db-065456
42. Tbc11251 / Tbc-11251
43. Cas-184036-34-8
44. Ft-0701871
45. D07171
46. A927076
47. Q905664
48. Sr-01000945028
49. Sr-01000945028-1
50. 2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic Acid (4-chloro-3-methyl-isoxazol-5-yl) Amide
51. 2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic Acid (4-chloro-3-methyl-isoxazol-5-yl)-amide
52. 2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic Acid (4-chloro-3-methyl-isoxazol-5-yl)-amide (sitaxsentan)
53. N- (4- Chloro- 3- Methyl- Oxazol- 5- Yl)- 2- [2- (6- Methylbenzo[1,3]dioxol- 5- Yl)acetyl]- Thiophene- 3- Sulfonamide
54. N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide.
55. N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2h-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
56. N-(4-chloro-3-methyl-5-isoxazolyl)-2-[(6-methyl-1,3-benzodioxol-5-yl) Acetyl]-3-thiophenesulphonamide
57. N-(4-chloro-3-methyloxazol-5-yl)-2-[2-(6-methylbenzo[1,3]dioxol-5-yl)acetyl]thiophene-3-sulfonamide
| Molecular Weight | 454.9 g/mol |
|---|---|
| Molecular Formula | C18H15ClN2O6S2 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 454.0060062 g/mol |
| Monoisotopic Mass | 454.0060062 g/mol |
| Topological Polar Surface Area | 144 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 720 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.
Sitaxentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Sitaxentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.
Endothelin Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)
C - Cardiovascular system
C02 - Antihypertensives
C02K - Other antihypertensives
C02KX - Antihypertensives for pulmonary arterial hypertension
C02KX03 - Sitaxentan
Absorption
70-100%
Route of Elimination
Renal (50 to 60%) Fecal (40 to 50%)
Hepatic (CYP2C9- and CYP3A4-mediated)
10 hours
Sitaxentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Sitaxentan decreases pulmonary vascular resistance. Sitaxentan has a higher affinity for ET-A than ET-B.
ABOUT THIS PAGE
95
PharmaCompass offers a list of Sitaxentan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sitaxentan manufacturer or Sitaxentan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sitaxentan manufacturer or Sitaxentan supplier.
PharmaCompass also assists you with knowing the Sitaxentan API Price utilized in the formulation of products. Sitaxentan API Price is not always fixed or binding as the Sitaxentan Price is obtained through a variety of data sources. The Sitaxentan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sitaxentan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sitaxentan, including repackagers and relabelers. The FDA regulates Sitaxentan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sitaxentan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sitaxentan supplier is an individual or a company that provides Sitaxentan active pharmaceutical ingredient (API) or Sitaxentan finished formulations upon request. The Sitaxentan suppliers may include Sitaxentan API manufacturers, exporters, distributors and traders.
Sitaxentan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sitaxentan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sitaxentan GMP manufacturer or Sitaxentan GMP API supplier for your needs.
A Sitaxentan CoA (Certificate of Analysis) is a formal document that attests to Sitaxentan's compliance with Sitaxentan specifications and serves as a tool for batch-level quality control.
Sitaxentan CoA mostly includes findings from lab analyses of a specific batch. For each Sitaxentan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sitaxentan may be tested according to a variety of international standards, such as European Pharmacopoeia (Sitaxentan EP), Sitaxentan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sitaxentan USP).
